Caribou Biosciences (CRBU) Total Liabilities (2020 - 2026)
Caribou Biosciences (CRBU) posted quarterly Total Liabilities of $47.0 million for Q1 2026, down 16.75% year-over-year from $56.4 million in Q1 2025, and down 11.68% quarter-over-quarter from $53.2 million in Q4 2025.
Caribou Biosciences (CRBU) Total Liabilities (2020 - 2026) Analysis & Trends
Caribou Biosciences (CRBU) has reported Total Liabilities for 7 consecutive years, with $47.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities fell 16.75% year-over-year to $47.0 million; the TTM figure through Mar 2026 stood at $47.0 million (down 16.75% YoY), while the FY2025 annual figure was $53.2 million, down 11.88% from the prior year.
- Total Liabilities retreated to $47.0 million in Q1 2026 per CRBU's latest filing, from $53.2 million in the prior quarter.
- Across five years, Total Liabilities topped out at $80.2 million in Q2 2023 and bottomed at $47.0 million in Q1 2026.
- Historically, Total Liabilities has averaged $63.6 million across 5 years, with a median of $63.1 million in 2024.
- Annual changes were most pronounced in 2022 — Total Liabilities soared 33.67% — and 2024, when it declined 22.09%.
- Caribou Biosciences' Total Liabilities stood at $72.9 million in 2022, then retreated by 12.46% to $63.8 million in 2023, then dropped by 5.4% to $60.4 million in 2024, then retreated by 11.88% to $53.2 million in 2025, then declined by 11.68% to $47.0 million in 2026.
- Business Quant data shows CRBU's Total Liabilities at $47.0 million in Q1 2026, $53.2 million in Q4 2025, and $53.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.59 Bn | 131.73 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.21 Bn | 78.22 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.65 Bn | 60.47 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 57.67 Bn | 52.53 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.90 Bn | 9.51 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 10.03 Bn |
| 10 | Caribou Biosciences | 167.65 Mn | 55.33 Mn | - | 44.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 44.67 Mn |
| Mar 31, 2026 | 46.98 Mn |
| Dec 31, 2025 | 53.19 Mn |
| Sep 30, 2025 | 53.14 Mn |
| Jun 30, 2025 | 54.77 Mn |
| Mar 31, 2025 | 56.43 Mn |
| Dec 31, 2024 | 60.36 Mn |
| Sep 30, 2024 | 63.13 Mn |
| Jun 30, 2024 | 62.47 Mn |
| Mar 31, 2024 | 63.54 Mn |
| Dec 31, 2023 | 63.81 Mn |
| Sep 30, 2023 | 59.25 Mn |
| Jun 30, 2023 | 80.19 Mn |
| Mar 31, 2023 | 69.19 Mn |
| Dec 31, 2022 | 72.89 Mn |
| Sep 30, 2022 | 74.71 Mn |
| Jun 30, 2022 | 73.48 Mn |
| Mar 31, 2022 | 74.20 Mn |
| Dec 31, 2021 | 54.53 Mn |
| Sep 30, 2021 | 57.56 Mn |